↓ Skip to main content

Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoni

Overview of attention for article published in Parasites & Vectors, August 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
48 Dimensions

Readers on

mendeley
68 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoni
Published in
Parasites & Vectors, August 2015
DOI 10.1186/s13071-015-1023-y
Pubmed ID
Authors

Noemi Cowan, Jennifer Keiser

Abstract

Drug discovery for the neglected tropical disease schistosomiasis has a high priority. Anticancer drugs, especially protein kinase inhibitors, might serve as a starting point for drug discovery owing to the importance of protein kinases in helminth growth and development. Furthermore, the Schistosoma mansoni genome encodes several genes for targets of drugs marketed for human use, including several anticancer drugs. In this study, we screened the approved oncology drug set of the National Cancer Institute's Developmental Therapeutic Program for antischistosomal activity. Drugs were tested in vitro against the larval and adult stage of S. mansoni. IC50 values and albumin binding were determined for active compounds. Lead compounds were tested in the chronic S. mansoni mouse model. Eleven of the 114 compounds tested revealed IC50 values ≤ 10 μM against both S. mansoni stages. Five of these lost activity against adult S. mansoni in the presence of serum albumin. Of 6 compounds studied in vivo, the highest activity was observed from two kinase inhibitors trametinib, and vandetanib, which reduced worm burden by 63.6 and 48.1 % respectively, after a single oral dose of 400 mg/kg body weight. Our study has confirmed that oncology drugs possess antischistosomal activity. There is space for further investigation, including elucidation of the mechanisms of action of schistosome-active cancer drugs, application of different treatment courses, and structure-activity relationship studies for improving drug potency.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 2 3%
Switzerland 1 1%
Unknown 65 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 13 19%
Student > Bachelor 10 15%
Researcher 10 15%
Student > Ph. D. Student 9 13%
Other 6 9%
Other 13 19%
Unknown 7 10%
Readers by discipline Count As %
Chemistry 13 19%
Agricultural and Biological Sciences 11 16%
Biochemistry, Genetics and Molecular Biology 8 12%
Medicine and Dentistry 8 12%
Immunology and Microbiology 6 9%
Other 8 12%
Unknown 14 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 August 2015.
All research outputs
#2,723,546
of 5,482,709 outputs
Outputs from Parasites & Vectors
#807
of 1,733 outputs
Outputs of similar age
#94,772
of 191,633 outputs
Outputs of similar age from Parasites & Vectors
#49
of 115 outputs
Altmetric has tracked 5,482,709 research outputs across all sources so far. This one is in the 47th percentile – i.e., 47% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,733 research outputs from this source. They receive a mean Attention Score of 3.4. This one is in the 46th percentile – i.e., 46% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 191,633 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 115 others from the same source and published within six weeks on either side of this one. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.